Adipose tissue hormones

Czech version

Authors: M. Haluzík ¹; P. Trachta ¹; D. Haluzíková ^1,2
Authors‘ workplace: III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MU Dr. Štěpán Svačina, DrSc., MBA ¹; Ústav tělovýchovného lékařství 1. lékařské fakulty UK a VFN Praha, přednosta doc. MU Dr. Zdeněk Vilikus, CSc. ²
Published in: Vnitř Lék 2010; 56(10): 1028-1034
Category: Obesity 2010

Overview

Adipose tissue had been traditionally considered a passive energy storage site without direct influence on energy homeostasis regulation. This view has been principally changed during early nineties by the discovery of hormonal production of adipose tissue. At present, the list of hormonally active substances of adipose tissue includes more than one hundred factors with paracrine or endocrine activity that play an important role in metabolic, food intake a inflammatory regulations and many other processes. Only minority of adipose tissue- derived hormones is produced exclusively in fat. Most of these factors is primarily put out by other tissues and organs. Adipose tissue- derived hormones are produced not only by adipocytes but also by preadipocytes, immunocompetent and endothelial cells and other cell types residing in fat. This paper summarizes current knowledge about endocrine function of adipose tissue with special respect to its changes in obesity. It also describes its possible role in the ethiopathogenesis of insulin resistance, atherosclerosis and other obesity‑related pathologies.

Key words:
adipose tissue – endocrine function – leptin – adiponectin – obesity – atherosclerosis

Sources

1. Zhang Y, Proenca R, Maffei M et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425– 432.

2. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor‑alpha: direct role in obesity‑linked insulin resistance. Science 1993; 259: 87– 91.

3. Hotamisligil GS, Arner P, Caro JF et al. Increased adipose tissue expression of tumor necrosis factor‑alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409– 2415.

4. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002; 13: 51– 59.

5. Svačina S, Owen K. Syndrom inzulínové rezistence. Praha: Triton 2003.

6. Reitman ML, Mason MM, Moitra J et al. Transgenic mice lacking white fat: models for understanding human lipoatrophic diabetes. Ann N Y Acad Sci 1999; 892: 289– 296.

7. Garg A, Vinaitheerthan M, Weatherall PT et al. Phenotypic heterogeneity in patients with familial partial lipodystrophy (dunnigan variety) related to the site of missense mutations in lamin a/ c gene. J Clin Endocrinol Metab 2001; 86: 59– 65.

8. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171– 176.

9. Oral EA, Simha V, Ruiz E et al. Leptin‑replacement therapy for lipodystrophy. N Engl J Med 2002; 346: 570– 578.

10. Stewart PM, Boulton A, Kumar S et al. Cortisol metabolism in human obesity: impaired cortisone – – > cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999; 84: 1022– 1027.

11. Macciò A, Madeddu C, Mantovani G. Adipose tissue as target organ in the treatment of hormone‑ dependent breast cancer: new therapeutic perspectives. Obes Rev 2009; 10: 660– 670.

12. Müllerová D, Kopecký J. White adipose tissue: storage and effector site for environmental pollutants. Physiol Res 2007; 56: 375– 381.

13. Haluzík M. Poruchy výživy a leptin. Praha: Grada Publishing 2002.

14. Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci 2002; 967: 363– 378.

15. Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity‑related insulin resistance. J Clin Invest 2003; 112: 1821– 1830.

16. Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796– 1808.

17. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 2003; 92: 18J– 26J.

18. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175– 184.

19. Després JP. Cardiovascular disease under the influence of excess visceral fat. Crit Pathw Cardiol 2007; 6: 51– 59.

20. Kremen J, Dolinkova M, Krajickova J et al. Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: possible role in postoperative insulin resistance. J Clin Endocrinol Metab 2006; 91: 4620– 4627.

21. Curat CA, Wegner V, Sengenès C et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744– 747.

22. Dolinková M, Dostálová I, Lacinová Zet al. The endocrine profile of subcutaneous and visceral adipose tissue of obese patients. Mol Cell Endocrinol 2008; 291: 63– 70.

23. Lacinová Z, Michalský D, Kasalický M et al. The influence of obesity on the gene expression of adiponectin and its receptor in subcutaneous adipose tissue. Vnitř Lék 2007; 53: 1190– 1197.

24. Haluzíková D, Haluzík M, Nedvídková J et al. Effect of physical activity on serum leptin levels. Sb Lék 2000; 101: 89– 92.

25. Ravussin E, Smith SR, Mitchell JA et al. Enhanced weight loss with pramlintide/ metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009; 17: 1736– 1743.

26. Aizawa‑ Abe M, Ogawa Y, Masuzaki H et al. Pathophysiological role of leptin in obesity‑related hypertension. J Clin Invest 2000; 105: 1243– 1252.

27. Trujillo ME, Scherer PE. Adiponectin – journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257: 167– 175.

28. Polak J, Kovacova Z, Holst C et al. Total adiponectin and adiponectin multimeric complexes in relation to weight loss‑induced improvements in insulin sensitivity in obese women: the NUGENOB study. Eur J Endocrinol 2008; 158: 533– 541.

29. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose‑specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595– 1599.

30. Haluzikova D, Roubicek T, Haluzik M. Adiponectin and atherosclerosis. Vnitř Lék 2007; 53: 359– 363.

31. Housova J, Anderlova K, Krizova J et al. Serum adiponectin and resistin concentrations in patients with restrictive and binge/ purge form of anorexia nervosa and bulimia nervosa. J Clin Endocrinol Metab 2005; 90: 1366– 1370.

32. Housová J, Housa D, Haluzík M. Adiponektin – nový adipocytární hormon se vztahem k obezite a inzulínové rezistenci. Vnitř Lék 2005; 51: 221– 225.

33. Maeda N, Takahashi M, Funahashi T et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose‑derived protein. Diabetes 2001; 50: 2094– 2099.

34. Haluzik M, Svacina Š. Metabolický syndrom a nukleární receptory PPAR. Praha: Grada Publishing 2005.

35. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307– 312.

36. Savage DB, Sewter CP, Klenk ES et al. Resistin/ Fizz3 expression in relation to obesity and peroxisome proliferator‑activated receptor‑ gamma action in humans. Diabetes 2001; 50: 2199– 2202.

37. Haluzik M, Haluzikova D. The role of resistin in obesity‑induced insulin resistance. Curr Opin Investig Drugs 2006; 7: 306– 311.

38. Senolt L, Housa D, Vernerova Z et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007; 66: 458– 463.

39. Engeli S, Schling P, Gorzelniak K et al. The adipose‑tissue renin‑angiotensin‑aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003; 35: 807– 825.

40. Roubicek T, Dolinkova M, Blaha J et al. Increased angiotensinogen production in epicardial adipose tissue during cardiac surgery: possible role in a postoperative insulin resistance. Physiol Res 2008; 57: 911– 917.

41. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin‑Angiotensin system. Drugs 2004; 64: 2537– 2565.

42. Housa D, Housova J, Vernerova Z et al. Adipocytokines and cancer. Physiol Res 2006; 55: 233– 244.

43. Xu A, Wang Y, Xu JY et al. Adipocyte fatty acid‑binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52: 405– 413.

44. Boord JB, Maeda K, Makowski L et al. Combined adipocyte‑ macrophage fatty acid‑binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E‑ deficient mice. Circulation 2004; 110: 1492– 1498.

45. Graham TE, Yang Q, Blüher M et al. Retinol‑binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 2552– 2563.

46. Dostalova I, Haluzikova D, Haluzik M. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/ type 2 diabetes mellitus. Physiol Res 2009; 58: 1– 7.

47. Kharitonenkov A, Shanafelt AB. Fibroblast growth factor‑ 21 as a therapeutic agent for metabolic diseases. Bio Drugs 2008; 22: 37– 44.

48. Farooqi IS, Matarese G, Lord GM et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/ metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093– 1103.

49. Pajvani UB, Hawkins M, Combs TP et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione‑ mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152– 12162.